Latus Bio

Latus Bio is a gene therapy company focused on developing innovative treatments for central nervous system (CNS) disorders. They are utilizing a novel approach by screening millions of adeno-associated virus (AAV) capsid variants to develop highly specific and potent gene delivery vehicles. Their aim is to overcome the limitations of traditional AAV therapies, including off-target effects and immune responses, by precisely targeting the desired cells and tissues.

Latus Bio's pipeline includes gene therapy candidates for Huntington's Disease and CLN2, with a focus on increasing efficacy, prioritizing patient well-being, and optimizing administration. Their team is composed of industry-leading scientists, clinicians, and professionals, and they have established partnerships with organizations like the Huntington's Disease Foundation. Latus Bio is dedicated to revolutionizing gene therapies and delivering transformative treatments for patients suffering from CNS disorders.

Latus Bio develops innovative gene therapy candidates for central nervous system (CNS) diseases. They utilize a novel approach that involves screening millions of adeno-associated virus (AAV) capsid variants to create highly specific and potent delivery vehicles. This technology aims to improve the treatment of CNS disorders by reducing the risks of immunogenicity and toxicity, enabling precise targeting, and minimizing the need for frequent administrations.

Latus Bio promotes a culture focused on innovation and collaboration, driven by a shared passion for developing groundbreaking gene therapies. The company values scientific excellence and precision, with a commitment to improving patient lives through transformative treatments. This translates into a dynamic and supportive environment where diverse perspectives are valued, fostering creativity and teamwork towards achieving ambitious goals.